New Risk • Jun 09
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 8.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company. Tillkännagivande • May 09
5N Plus Announces Election of Board Members 5N Plus Inc. at its Annual General Meeting of Shareholders held on May 7, 2026, the directors appointed Mr. Gervais Jacques as Executive Chairman of the Board of Directors of the Company. Michael Hanley and Richard Perron appointed as directors. Reported Earnings • May 07
First quarter 2026 earnings released: EPS: US$0.20 (vs US$0.11 in 1Q 2025) First quarter 2026 results: EPS: US$0.20 (up from US$0.11 in 1Q 2025). Revenue: US$117.9m (up 33% from 1Q 2025). Net income: US$17.8m (up 86% from 1Q 2025). Profit margin: 15% (up from 11% in 1Q 2025). The increase in margin was driven by higher revenue. Revenue is forecast to grow 14% p.a. on average during the next 2 years, compared to a 3.5% growth forecast for the Chemicals industry in Germany. Tillkännagivande • Apr 29
5N Plus Inc. to Report Q1, 2026 Results on May 06, 2026 5N Plus Inc. announced that they will report Q1, 2026 results at 4:00 PM, US Eastern Standard Time on May 06, 2026 Buy Or Sell Opportunity • Apr 23
Now 20% undervalued Over the last 90 days, the stock has risen 72% to €20.48. The fair value is estimated to be €25.70, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 15% over the last 3 years. Meanwhile, the company has become profitable. Revenue is forecast to grow by 37% in 2 years. Earnings are forecast to grow by 43% in the next 2 years. Tillkännagivande • Apr 14
5N Plus Inc. Announces Chief Financial Officer Changes 5N Plus Inc. announced the appointment of Mr. Alban Fournier as Chief Financial Officer, effective April 27, 2026. Mr. Fournier joins 5N+ with nearly 30 years of experience across three continents in corporate and operational roles, with deep expertise in finance, internal audit, corporate strategy and technology. He most recently served as Chief Financial and Technology Officer at the Montreal Port Authority, where he also oversaw procurement. Previously, he was CFO at Chantier Davie Canada Inc. Prior to that, he spent more than two decades with Rio Tinto, where he held several senior leadership roles, including group head of internal audit and CFO of Rio Tinto Bauxite & Alumina. A graduate of Sciences Po Paris (Paris Institute of Political Studies), he holds a master's degree in finance and economics. This appointment follows the Company's previously announced leadership succession plan under which Richard Perron, current CFO, will become President and Chief Executive Officer (CEO) and Gervais Jacques, current CEO, will become Executive Chair of the Board effective May 31, 2026. Buy Or Sell Opportunity • Mar 30
Now 26% undervalued Over the last 90 days, the stock has risen 68% to €18.66. The fair value is estimated to be €25.38, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 15% over the last 3 years. Meanwhile, the company has become profitable. Revenue is forecast to grow by 36% in 2 years. Earnings are forecast to grow by 42% in the next 2 years. Valuation Update With 7 Day Price Move • Mar 26
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to €21.60, the stock trades at a forward P/E ratio of 38x. Average forward P/E is 14x in the Chemicals industry in Germany. Simply Wall St's valuation model estimates the intrinsic value at €25.10 per share. Tillkännagivande • Mar 18
5N Plus Inc. Announces Jean-Marie Bourassa, Member of the Board Will Not Be Standing for Re-Election 5N Plus Inc. announced that Mr. Jean-Marie Bourassa, member of the Board since 2007, will not be standing for re-election. Recent Insider Transactions • Mar 06
Independent Director recently sold €19m worth of stock On the 2nd of March, Jean-Marie Bourassa sold around 1m shares on-market at roughly €18.86 per share. This transaction amounted to 76% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €20m more than they bought in the last 12 months. Buy Or Sell Opportunity • Mar 04
Now 22% undervalued Over the last 90 days, the stock has risen 60% to €18.84. The fair value is estimated to be €24.20, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 15% over the last 3 years. Meanwhile, the company has become profitable. Revenue is forecast to grow by 36% in 2 years. Earnings are forecast to grow by 42% in the next 2 years. Tillkännagivande • Mar 03
5N Plus Inc., Annual General Meeting, May 07, 2026 5N Plus Inc., Annual General Meeting, May 07, 2026. Reported Earnings • Feb 26
Full year 2025 earnings released: EPS: US$0.57 (vs US$0.17 in FY 2024) Full year 2025 results: EPS: US$0.57 (up from US$0.17 in FY 2024). Revenue: US$391.1m (up 35% from FY 2024). Net income: US$50.6m (up 245% from FY 2024). Profit margin: 13% (up from 5.1% in FY 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 14% p.a. on average during the next 2 years, compared to a 2.4% growth forecast for the Chemicals industry in Germany. Tillkännagivande • Feb 17
5N Plus Inc. to Report Q4, 2025 Results on Feb 24, 2026 5N Plus Inc. announced that they will report Q4, 2025 results on Feb 24, 2026 Valuation Update With 7 Day Price Move • Jan 30
Investor sentiment improves as stock rises 20% After last week's 20% share price gain to €14.20, the stock trades at a forward P/E ratio of 28x. Average forward P/E is 12x in the Chemicals industry in Germany. Total returns to shareholders of 166% over the past year. Simply Wall St's valuation model estimates the intrinsic value at €16.36 per share. Valuation Update With 7 Day Price Move • Jan 12
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to €12.86, the stock trades at a forward P/E ratio of 24x. Average forward P/E is 14x in the Chemicals industry in Germany. Simply Wall St's valuation model estimates the intrinsic value at €18.34 per share. Buy Or Sell Opportunity • Nov 06
Now 22% undervalued Over the last 90 days, the stock has risen 20% to €12.22. The fair value is estimated to be €15.72, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 11% over the last 3 years. Meanwhile, the company has become profitable. Revenue is forecast to grow by 32% in 2 years. Earnings are forecast to grow by 35% in the next 2 years. Reported Earnings • Nov 04
Third quarter 2025 earnings released: EPS: US$0.20 (vs US$0.072 in 3Q 2024) Third quarter 2025 results: EPS: US$0.20 (up from US$0.072 in 3Q 2024). Revenue: US$104.9m (up 33% from 3Q 2024). Net income: US$18.2m (up 185% from 3Q 2024). Profit margin: 17% (up from 8.1% in 3Q 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 2.5% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 104% per year whereas the company’s share price has increased by 102% per year. Tillkännagivande • Oct 27
5N Plus Inc. to Report Q3, 2025 Results on Nov 03, 2025 5N Plus Inc. announced that they will report Q3, 2025 results at 4:00 PM, US Eastern Standard Time on Nov 03, 2025 Valuation Update With 7 Day Price Move • Aug 11
Investor sentiment improves as stock rises 28% After last week's 28% share price gain to €10.18, the stock trades at a forward P/E ratio of 24x. Average forward P/E is 13x in the Chemicals industry in Germany. Reported Earnings • Aug 05
Second quarter 2025 earnings released: EPS: US$0.17 (vs US$0.054 in 2Q 2024) Second quarter 2025 results: EPS: US$0.17 (up from US$0.054 in 2Q 2024). Revenue: US$95.3m (up 28% from 2Q 2024). Net income: US$15.2m (up 218% from 2Q 2024). Profit margin: 16% (up from 6.4% in 2Q 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 7.2% p.a. on average during the next 3 years, compared to a 3.4% growth forecast for the Chemicals industry in Germany. Tillkännagivande • Jul 28
5N Plus Inc. to Report Q2, 2025 Results on Aug 04, 2025 5N Plus Inc. announced that they will report Q2, 2025 results After-Market on Aug 04, 2025 Valuation Update With 7 Day Price Move • Jul 18
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to €6.86, the stock trades at a forward P/E ratio of 25x. Average forward P/E is 14x in the Chemicals industry in Germany. Valuation Update With 7 Day Price Move • Jun 16
Investor sentiment improves as stock rises 22% After last week's 22% share price gain to €5.97, the stock trades at a forward P/E ratio of 22x. Average forward P/E is 16x in the Chemicals industry in Germany. Total returns to shareholders of 402% over the past three years. Reported Earnings • May 09
First quarter 2025 earnings released: EPS: US$0.11 (vs US$0.028 in 1Q 2024) First quarter 2025 results: EPS: US$0.11 (up from US$0.028 in 1Q 2024). Revenue: US$88.9m (up 37% from 1Q 2024). Net income: US$9.57m (up 282% from 1Q 2024). Profit margin: 11% (up from 3.9% in 1Q 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 7.8% p.a. on average during the next 3 years, compared to a 3.5% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 97% per year but the company’s share price has only increased by 67% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Apr 29
Investor sentiment improves as stock rises 25% After last week's 25% share price gain to €4.23, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 14x in the Chemicals industry in Germany. Total returns to shareholders of 204% over the past three years. Tillkännagivande • Apr 29
5N Plus Inc. to Report Q1, 2025 Results on May 07, 2025 5N Plus Inc. announced that they will report Q1, 2025 results After-Market on May 07, 2025 Valuation Update With 7 Day Price Move • Apr 01
Investor sentiment deteriorates as stock falls 37% After last week's 37% share price decline to €3.39, the stock trades at a forward P/E ratio of 14x. Average forward P/E is 15x in the Chemicals industry in Germany. Total returns to shareholders of 98% over the past three years. Tillkännagivande • Mar 04
5N Plus Inc., Annual General Meeting, May 08, 2025 5N Plus Inc., Annual General Meeting, May 08, 2025. Tillkännagivande • Feb 18
5N Plus Inc. to Report Q4, 2024 Results on Feb 25, 2025 5N Plus Inc. announced that they will report Q4, 2024 results After-Market on Feb 25, 2025 Valuation Update With 7 Day Price Move • Jan 29
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to €5.34, the stock trades at a forward P/E ratio of 23x. Average forward P/E is 12x in the Chemicals industry in Germany. Total returns to shareholders of 228% over the past three years. Reported Earnings • Nov 07
Third quarter 2024 earnings released: EPS: US$0.07 (vs US$0.017 in 3Q 2023) Third quarter 2024 results: EPS: US$0.07 (up from US$0.017 in 3Q 2023). Revenue: US$78.8m (up 25% from 3Q 2023). Net income: US$6.37m (up 320% from 3Q 2023). Profit margin: 8.1% (up from 2.4% in 3Q 2023). Revenue is forecast to grow 9.4% p.a. on average during the next 3 years, compared to a 4.3% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 73% per year but the company’s share price has only increased by 35% per year, which means it is significantly lagging earnings growth. Tillkännagivande • Oct 28
5N Plus Inc. to Report Q3, 2024 Results on Nov 04, 2024 5N Plus Inc. announced that they will report Q3, 2024 results After-Market on Nov 04, 2024 Recent Insider Transactions • Sep 19
Chief Financial Officer recently sold €581k worth of stock On the 11th of September, Richard Perron sold around 125k shares on-market at roughly €4.64 per share. This transaction amounted to 100% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Richard has been a net seller over the last 12 months, reducing personal holdings by €377k. Tillkännagivande • Jul 29
5N Plus Inc. to Report Q2, 2024 Results on Aug 05, 2024 5N Plus Inc. announced that they will report Q2, 2024 results After-Market on Aug 05, 2024 Tillkännagivande • May 11
5N Plus Inc. Appoints Andrée-Lise Méthot as Director 5N Plus Inc. announced that at its Annual General Meeting of Shareholders held on May 9, 2024, Approved the appointment of Andrée-Lise Méthot as director. Tillkännagivande • May 01
5N Plus Inc. to Report Q1, 2024 Results on May 06, 2024 5N Plus Inc. announced that they will report Q1, 2024 results at 4:00 PM, US Eastern Standard Time on May 06, 2024 Tillkännagivande • Mar 24
5N Plus Inc. Launches the Commercialization Rights for Its Portfolio of Gallium Nitride on Silicon (Gan-On-Si) Patents 5N Plus Inc. announced that it is officially launching the commercialization rights for its portfolio of gallium nitride on silicon (GaN-on-Si) patents that will take semiconductors and power switching technology to the next level. These key patents can enable the rapid prototype development and first-to-market commercialization of novel vertical GaN-on-Si power devices by companies operating in the High-Power Electronics (HPE), Electric Vehicles (EV) and Artificial Intelligence (AI) server sectors. A mechanically stable, wide-bandgap semiconductor material with high heat capacity and thermal conductivity, GaN has outstanding properties. Today, lateral GaN is primarily used in low voltage (<400V) applications, such as chargers, but novel vertical GaN- on-Si has the potential to replace silicon carbide (SiC), which is the current preferred material for medium and high voltage applications (i.e. EV inverters operating 650V). SiC is expensive and not easily available, whereas GaN-on-Si is more efficient and cost-effective. Recent academic demonstrations utilizing key 5N+ patents have shown that vertical GaN-on- Si, as opposed to lateral GaN transistors showing destructive breakdown, offers soft breakdown with avalanche capability for safe, compact and more efficient devices. Also included in this patent is the ability to remove the substrate to form the backside contacts once the GaN growth is complete. In addition, the Company holds lateral GaN-on-Si patents for radiofrequency (RF) applications that will enable next generation 5G and 6G wireless communication components. 5N+ holds these patents through its wholly owned subsidiary AZUR SPACE Solar Power GmbH, a leader in multi-junction solar cell technology. About 5N+ is a leading global producer of specialty semiconductors and performance materials. The Company's ultra-pure materials often form the core element of its customers' products. These customers rely on 5N+'s products to enable performance and sustainability in their own products. 5N+ deploys a range of proprietary and proven technologies to develop and manufacture its products. The Company's products enable various applications in several key industries, including renewable energy, security, space, pharmaceutical, medical imaging and industrial. Headquartered in Montreal, Quebec, 5N+ operates R&D, manufacturing and commercial centers in strategically located facilities around the world including Europe, North America and Asia. Tillkännagivande • Mar 02
5N Plus Inc., Annual General Meeting, May 09, 2024 5N Plus Inc., Annual General Meeting, May 09, 2024. Tillkännagivande • Mar 01
5N Plus Inc. Reports Impairment Results for the Fourth Quarter of 2023 5N Plus Inc. reported impairment results for the fourth quarter of 2023. for the quarter, the company reported impairment of $64,000. Tillkännagivande • Feb 21
5N Plus Inc. to Report Q4, 2023 Results on Feb 27, 2024 5N Plus Inc. announced that they will report Q4, 2023 results After-Market on Feb 27, 2024 Tillkännagivande • Nov 01
5N Plus Inc. to Report Q3, 2023 Results on Nov 07, 2023 5N Plus Inc. announced that they will report Q3, 2023 results at 4:00 PM, US Eastern Standard Time on Nov 07, 2023 Tillkännagivande • Jul 26
5N Plus Inc. to Report Q2, 2023 Results on Aug 01, 2023 5N Plus Inc. announced that they will report Q2, 2023 results at 4:00 PM, US Eastern Standard Time on Aug 01, 2023 Tillkännagivande • Feb 15
5N Plus Inc. to Report Q4, 2022 Results on Feb 21, 2023 5N Plus Inc. announced that they will report Q4, 2022 results After-Market on Feb 21, 2023 Reported Earnings • Nov 03
Third quarter 2022 earnings released: US$0.079 loss per share (vs US$0.01 loss in 3Q 2021) Third quarter 2022 results: US$0.079 loss per share (further deteriorated from US$0.01 loss in 3Q 2021). Revenue: US$66.4m (up 31% from 3Q 2021). Net loss: US$6.97m (loss widened US$6.18m from 3Q 2021). Revenue is forecast to grow 11% p.a. on average during the next 3 years, while revenues in the Chemicals industry in Germany are expected to remain flat. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 106 percentage points per year, which is a significant difference in performance. Recent Insider Transactions • May 27
Independent Chairman recently bought €87k worth of stock On the 20th of May, Luc Bertrand bought around 100k shares on-market at roughly €0.87 per share. In the last 3 months, there was an even bigger purchase from another insider worth €116k. Luc has been a buyer over the last 12 months, purchasing a net total of €284k worth in shares. Reported Earnings • May 06
First quarter 2022 earnings released: US$0.07 loss per share (vs US$0.009 profit in 1Q 2021) First quarter 2022 results: US$0.07 loss per share (down from US$0.009 profit in 1Q 2021). Revenue: US$64.4m (up 37% from 1Q 2021). Net loss: US$5.76m (down US$6.52m from profit in 1Q 2021). Over the next year, revenue is forecast to grow 16%, compared to a 8.5% growth forecast for the industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 50 percentage points per year, which is a significant difference in performance. Recent Insider Transactions • Mar 16
Interim President recently bought €116k worth of stock On the 14th of March, Gervais Jacques bought around 77k shares on-market at roughly €1.50 per share. This was the largest purchase by an insider in the last 3 months. This was Gervais' only on-market trade for the last 12 months. Reported Earnings • Feb 24
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Full year 2021 results: EPS: US$0.04 (up from US$0.027 in FY 2020). Revenue: US$210.0m (up 19% from FY 2020). Net income: US$3.11m (up 42% from FY 2020). Profit margin: 1.5% (up from 1.2% in FY 2020). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 3.6%. Over the next year, revenue is forecast to grow 29%, compared to a 6.6% growth forecast for the industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 54 percentage points per year, which is a significant difference in performance. Recent Insider Transactions • Dec 18
Independent Director recently bought €111k worth of stock On the 15th of December, Jean-Marie Bourassa bought around 75k shares on-market at roughly €1.48 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought €587k more in shares than they have sold in the last 12 months. Executive Departure • Dec 02
President, CEO & Non Independent Director Arjang Roshan has left the company On the 1st of December, Arjang Roshan's tenure as President, CEO & Non Independent Director of the company ended after 5.8 years in the role. As of September 2021, Arjang still personally held 267.00k shares (€486k worth at the time). Arjang is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 4.83 years. Under Arjang's leadership, the company delivered a total shareholder return of 92%. Reported Earnings • Nov 04
Third quarter 2021 earnings released: US$0.01 loss per share (vs US$0.033 profit in 3Q 2020) The company reported a soft third quarter result with weaker earnings and weaker control over costs, although revenues improved. Third quarter 2021 results: Revenue: US$50.8m (up 28% from 3Q 2020). Net loss: US$792.0k (down 129% from profit in 3Q 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 70 percentage points per year, which is a significant difference in performance. Reported Earnings • Aug 04
Second quarter 2021 earnings released: EPS US$0.03 (vs US$0.021 in 2Q 2020) The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: US$47.7m (up 16% from 2Q 2020). Net income: US$2.16m (up 23% from 2Q 2020). Profit margin: 4.5% (up from 4.3% in 2Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 58% per year but the company’s share price has only fallen by 7% per year, which means it has not declined as severely as earnings. Recent Insider Transactions • Jun 03
Independent Chairman recently bought €196k worth of stock On the 31st of May, Luc Bertrand bought around 100k shares on-market at roughly €1.96 per share. This was the largest purchase by an insider in the last 3 months. Luc has been a buyer over the last 12 months, purchasing a net total of €423k worth in shares. Recent Insider Transactions • May 20
Independent Chairman recently bought €155k worth of stock On the 17th of May, Luc Bertrand bought around 80k shares on-market at roughly €1.94 per share. This was the largest purchase by an insider in the last 3 months. Luc has been a buyer over the last 12 months, purchasing a net total of €461k worth in shares. Reported Earnings • May 11
First quarter 2021 earnings released: EPS US$0.01 (vs US$0.007 in 1Q 2020) The company reported a decent first quarter result with improved earnings and profit margins, although revenues were weaker. First quarter 2021 results: Revenue: US$46.9m (down 6.2% from 1Q 2020). Net income: US$763.0k (up 29% from 1Q 2020). Profit margin: 1.6% (up from 1.2% in 1Q 2020). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 55% per year but the company’s share price has increased by 8% per year, which means it is well ahead of earnings. Reported Earnings • Feb 25
Full year 2020 earnings released The company reported a decent full year result with improved earnings and profit margins, although revenues were weaker. Full year 2020 results: Revenue: US$177.2m (down 9.6% from FY 2019). Net income: US$2.19m (up 23% from FY 2019). Profit margin: 1.2% (up from 0.9% in FY 2019). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 47% per year but the company’s share price has increased by 16% per year, which means it is well ahead of earnings. Analyst Estimate Surprise Post Earnings • Feb 25
Revenue beats expectations Revenue exceeded analyst estimates by 3.9%. Over the next year, revenue is forecast to stay flat compared to a 5.1% growth forecast for the Chemicals industry in Germany. Is New 90 Day High Low • Feb 18
New 90-day high: €2.76 The company is up 82% from its price of €1.52 on 19 November 2020. The German market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 14% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €2.82 per share. Tillkännagivande • Feb 17
5N Plus Inc. to Report Q4, 2020 Results on Feb 23, 2021 5N Plus Inc. announced that they will report Q4, 2020 results After-Market on Feb 23, 2021 Valuation Update With 7 Day Price Move • Jan 29
Investor sentiment improved over the past week After last week's 18% share price gain to US$2.50, the stock is trading at a trailing P/E ratio of 48.8x, up from the previous P/E ratio of 41.4x. This compares to an average P/E of 27x in the Chemicals industry in Germany. Total returns to shareholders over the past three years are 60%. Is New 90 Day High Low • Jan 24
New 90-day high: €2.22 The company is up 78% from its price of €1.25 on 23 October 2020. The German market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 20% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €19.96 per share. Tillkännagivande • Jan 14
5N Plus Inc. Acquires Stake in Microbion Corporation and Secures Drug Substance Manufacturing Rights 5N Plus Inc. (5N Plus) and Microbion Corporation (Microbion) jointly announced that the parties have entered into a strategic relationship for the development, manufacturing and commercial drug substance supply of Microbion's new class of antibiotic and antibiofilm drugs. Under the terms of the agreement, 5N Plus has taken an equity stake in Microbion and will assume responsibility for the manufacturing of Bismuth-based Active Pharmaceutical Ingredients (API) required in Microbion's family of drug products currently under development, including the company's lead API, pravibismane. Microbion retains responsibility for the development, manufacturing and commercialization of the final drug products currently under development. In recent years, effective treatments for bacterial infections have become ever more critical, as some bacteria have become increasingly resistant to existing drug therapies. Microbion's approach has been to develop a new class of microbial bioenergetic inhibitors that arrest the activities of a broad range of offending pathogens. Pravibismane, the first in this new class of anti-infectives, has demonstrated impressive antibacterial and antibiofilm activity against a wide range of Gram-negative and Gram-positive pathogens, including multiple priority pathogens or "superbugs" as identified by the US Centers for Disease Control and Prevention (CDC). As the world's leading producer of Bismuth-based API compounds, 5N Plus is uniquely positioned to support Microbion in the development of this new class of compound. In the initial phase of the collaboration between the two companies, 5N Plus will be supporting Microbion's clinical development programs. Pravibismane suspension for topical/local administration is currently in Phase 2 for the treatment of diabetic foot ulcer infections and orthopedic-device infections. Inhaled pravibismane is in late pre-clinical studies for the treatment of chronic lung infections. The inhaled pravibismane program is receiving up to $17.1 million in non- dilutive development funding support from CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator) and the Cystic Fibrosis Foundation, as previously announced by Microbion. Microbion Corporation has closed a Series A financing of $25 million from GHS Fund (Quark Venture LP and GF Securities). Developing pravibismane for targeted, localized administration provides not only the ability to treat specific areas of severe unmet medical need, but also is an approach that can result in significant commercial opportunity within the anti-infectives field. Tillkännagivande • Jan 13
5N Plus Inc. (TSX:VNP) agreed to acquire an unknown stake in Microbion Corporation. 5N Plus Inc. (TSX:VNP) agreed to acquire an unknown stake in Microbion Corporation on January 12, 2021. Under the terms of the agreement, 5N Plus will assume responsibility for the manufacturing of Bismuth-based Active Pharmaceutical Ingredients (API) required in Microbion’s family of drug products currently under development, including the company’s lead API, pravibismane. Microbion retains responsibility for the development, manufacturing and commercialization of the final drug products currently under development.
5N Plus Inc. (TSX:VNP) completed the acquisition of an unknown stake in Microbion Corporation on January 12, 2021. Valuation Update With 7 Day Price Move • Jan 04
Investor sentiment improved over the past week After last week's 21% share price gain to US$1.99, the stock is trading at a trailing P/E ratio of 36.9x, up from the previous P/E ratio of 30.4x. This compares to an average P/E of 27x in the Chemicals industry in Germany. Total return to shareholders over the past three years is a loss of 2.5%. Is New 90 Day High Low • Dec 28
New 90-day high: €1.64 The company is up 49% from its price of €1.10 on 29 September 2020. The German market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 18% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €18.75 per share. Tillkännagivande • Nov 14
5N Plus Inc. Secures Multi-Year Semiconductor Supply Contracts in the Renewable Energy Sector 5N Plus Inc. announced that it has secured multi-year contracts for the supply of semiconductor materials associated with the manufacturing of thin-film photovoltaic (PV) modules by First Solar Inc. The terms of these contracts are structured asymmetrically with lower volumes anticipated in the earlier period of the contract. 5N Plus has been a key supplier of semiconductor materials to First Solar Inc., since 2007 and over this period several long-term contracts have been signed and successfully executed between the two companies. During this period 5N Plus has become the world leading supplier of engineered semiconductor compounds to the thin-film Renewable Energy Industry, enabling its customers to deliver reliable and cost-effective solutions to the market. 5N Plus semiconductor materials are imbedded in First Solar's Series 6 module in a specialty semiconductor stack which is 33 times thinner than the thickness of a human hair. The Series 6 module has a carbon footprint that is up to six times lower and a water footprint that is up to 24 times lower than crystalline silicon PV panels. Given the fact that a large portion of 5N Plus' production activity related to these semiconductor compounds is powered by renewable energy, Series 6 modules produced with 5N Plus semiconductor thin-film materials deliver the lowest carbon solar available on November 12, 2020. Analyst Estimate Surprise Post Earnings • Nov 11
Revenue misses expectations Revenue missed analyst estimates by 8.0%. Over the next year, revenue is forecast to grow 7.0%, compared to a 3.1% growth forecast for the Chemicals industry in Germany. Valuation Update With 7 Day Price Move • Nov 07
Market bids up stock over the past week After last week's 16% share price gain to US$1.44, the stock is trading at a trailing P/E ratio of 40.8x, up from the previous P/E ratio of 35.1x. This compares to an average P/E of 25x in the Chemicals industry in Germany. Total return to shareholders over the past three years is a loss of 28%. Is New 90 Day High Low • Nov 06
New 90-day high: €1.33 The company is up 15% from its price of €1.16 on 07 August 2020. The German market is down 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 4.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €14.23 per share. Tillkännagivande • Oct 30
5N Plus Inc. to Report Q3, 2020 Results on Nov 10, 2020 5N Plus Inc. announced that they will report Q3, 2020 results at 5:00 PM, Eastern Standard Time on Nov 10, 2020 Valuation Update With 7 Day Price Move • Oct 12
Market bids up stock over the past week After last week's 16% share price gain to US$1.31, the stock is trading at a trailing P/E ratio of 37x, up from the previous P/E ratio of 31.9x. This compares to an average P/E of 27x in the Chemicals industry in Germany. Total return to shareholders over the past three years is a loss of 38%. Is New 90 Day High Low • Oct 12
New 90-day high: €1.31 The company is up 20% from its price of €1.09 on 14 July 2020. The German market is up 2.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 9.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €2.59 per share. 
